BioSpace News Archive

This week, Theradaptive, a leading biotechnology company specializing in therapeutic delivery platforms, presents a new abstract demonstrating the efficacy and safety of the company’s novel AMP2 protein technology in rabbit PLF and sheep interbody fusion models.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the U.S. financial markets close.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 31,600 shares of the Company’s common stock at an exercise price per share of $20.68, which was the closing price on February 8, 2023, and restricted stock units to acquire a total of 15,800 shares of the Company’s common stock.

Minerva Surgical, Inc. announced that it has closed on the sale of 146,627,565 shares of its common stock in a private placement, led by Accelmed Partners, with participation by New Enterprise Associates, at an offering price of $0.2046 per share.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today announced the Company will present a corporate overview and host investor meetings at the SVB Securities Global Biopharma Conference and present on Thursday, February 16, 2023, at 12:00 p.m. ET/9:00 a.m. PT.

InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022.

BriaCell Therapeutics Corp. is pleased to announce the results of its annual general and special meeting of shareholders of the Company for the year ended July 31, 2022 held on February 9, 2023.

Addex Therapeutics announced notification from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement of $1.00 per ADS share under Nasdaq Listing Rule 5550 and currently meets all other applicable criteria for continued listing.

Roche announced that it has expanded its collaboration with Janssen Biotech Inc. to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

Ipsen, a global specialty-driven biopharmaceutical company, presents its financial results for the year and the fourth quarter of 2022.